Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being

Jakob P. Ley; Sabine Widder; Veronika Somoza; Barbara Lieder; Mathias Zaunschirm; Gerhard Krammer

Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being

Jakob P. Ley (Inventor), Sabine Widder (Inventor), Veronika Somoza (Inventor), Barbara Lieder (Inventor), Mathias Zaunschirm (Inventor), Gerhard Krammer (Inventor)

Department of Physiological Chemistry

Publications: Patent

Abstract

NOVELTY - A non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes, involves orally administering composition comprising at least one alkamide to a human or an animal being. USE - As non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes (claimed). ADVANTAGE - The composition reduces uptake of free fatty acids in the adipocytes and at the same time stimulates the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. The composition is thus perfectly suitable to counteract any undesired gain of weight. The alkamide compound counteracts overweight and its associated negative physical and mental factors. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) compositions for oral ingestion comprising at least one alkamide selected from 2E,4E-decadienic acid-N-isobutylamide (trans-pellitorine); 2E,4Z-decadienic acid-N-isobutylamide (cis-pellitorine); 2Z,4Z-decadienic acid-N-isobutylamide; 2Z,4E-decadienic acid-N-isobutylamide, 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2R)-2-methylbutylamide); 2E,4Z-decadienic acid-N-(2-methylbutyl)amide; 2E,4E-decadienic acid-N-piperidine (achilleamide); 2E-decenoic acid-N-isobutylamide; 2E,6Z,8E-decatrienoic acid N-isobutylamide (spilanthol); 2E,6Z,8E-decatrienoic acid N-((2S)-2-methylbutyl)amide (homospilanthol); 2E,6Z,8E-decatrienoic acid-N-((2R)-2-methylbutyl)amide; 2E-decen-4-inoic acid-N-isobutyl amide; 2Z-decen-4-inoic acid N-isobutyl amine; 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-methylpropyl)amide ( alpha -sanshool); 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( alpha -hydroxysanshool); 2E,6E,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( beta -hydroxysanshool; 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylpropyl)amide ( gamma -hydroxysanshool); 2E,4E,8E,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylprypyl)amide ( gamma -hydroxyisosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methyl-2-propenyl)amide ( gamma -dehydrosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methylpropyl)amide ( gamma -sanshool); 2E,4E,8Z,11Z-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (bungeanool), 2E,4E,8Z,11E-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (isobungeanool), 2E,4E,8Z-tetradecatrienoic acid N-(2-hydroxy-2-methylpropyl)amide (dihydrobungeanool) and 2E,4E-tetradecadienoic acid N-(2-hydroxy-2-methylpropyl)amide (tetrahydrobungeanool); and (2) use of alkamides as system to be orally ingested to reduce appetite and/or create a feeling of satiety and/or reduce the resorption of calories and/or for mood-enhancing purposes.

Original language	English
Patent number	US2014234412-A1; EP2767174-A1
IPC	A61K-031/16; A23L-001/30
Priority date	16/02/13
Publication status	Published - 21 Aug 2014

Austrian Fields of Science 2012

303009 Nutritional sciences

Fingerprint

Dive into the research topics of 'Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being'. Together they form a unique fingerprint.

Cite this

Ley, Jakob P. (Inventor) ; Widder, Sabine (Inventor) ; Somoza, Veronika (Inventor) et al. / Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being. Patent No.: US2014234412-A1; EP2767174-A1 . Aug 21, 2014.

@misc{f8f4ee8ca59a48f38b2ad3ddc764b19e,

title = "Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being",

abstract = "NOVELTY - A non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes, involves orally administering composition comprising at least one alkamide to a human or an animal being. USE - As non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes (claimed). ADVANTAGE - The composition reduces uptake of free fatty acids in the adipocytes and at the same time stimulates the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. The composition is thus perfectly suitable to counteract any undesired gain of weight. The alkamide compound counteracts overweight and its associated negative physical and mental factors. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) compositions for oral ingestion comprising at least one alkamide selected from 2E,4E-decadienic acid-N-isobutylamide (trans-pellitorine); 2E,4Z-decadienic acid-N-isobutylamide (cis-pellitorine); 2Z,4Z-decadienic acid-N-isobutylamide; 2Z,4E-decadienic acid-N-isobutylamide, 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2R)-2-methylbutylamide); 2E,4Z-decadienic acid-N-(2-methylbutyl)amide; 2E,4E-decadienic acid-N-piperidine (achilleamide); 2E-decenoic acid-N-isobutylamide; 2E,6Z,8E-decatrienoic acid N-isobutylamide (spilanthol); 2E,6Z,8E-decatrienoic acid N-((2S)-2-methylbutyl)amide (homospilanthol); 2E,6Z,8E-decatrienoic acid-N-((2R)-2-methylbutyl)amide; 2E-decen-4-inoic acid-N-isobutyl amide; 2Z-decen-4-inoic acid N-isobutyl amine; 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-methylpropyl)amide ( alpha -sanshool); 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( alpha -hydroxysanshool); 2E,6E,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( beta -hydroxysanshool; 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylpropyl)amide ( gamma -hydroxysanshool); 2E,4E,8E,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylprypyl)amide ( gamma -hydroxyisosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methyl-2-propenyl)amide ( gamma -dehydrosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methylpropyl)amide ( gamma -sanshool); 2E,4E,8Z,11Z-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (bungeanool), 2E,4E,8Z,11E-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (isobungeanool), 2E,4E,8Z-tetradecatrienoic acid N-(2-hydroxy-2-methylpropyl)amide (dihydrobungeanool) and 2E,4E-tetradecadienoic acid N-(2-hydroxy-2-methylpropyl)amide (tetrahydrobungeanool); and (2) use of alkamides as system to be orally ingested to reduce appetite and/or create a feeling of satiety and/or reduce the resorption of calories and/or for mood-enhancing purposes.",

author = "Ley, {Jakob P.} and Sabine Widder and Veronika Somoza and Barbara Lieder and Mathias Zaunschirm and Gerhard Krammer",

note = "Derwent Primary Accession Number: 2014-P72244 [59] ; US2014234412-A1; EP2767174-A1 ; A61K-031/16; A23L-001/30 ",

year = "2014",

month = aug,

day = "21",

language = "English",

type = "Patent",

}

Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being. / Ley, Jakob P. (Inventor); Widder, Sabine (Inventor); Somoza, Veronika (Inventor) et al.
Patent No.: US2014234412-A1; EP2767174-A1 . Aug 21, 2014.

Publications: Patent

TY - PAT

T1 - Non-therapeutic process for reduction of appetite or to create feeling of satiety or to reduce caloric resorption or for mood-enhancing purposes, involves orally administering composition comprising alkamide to human or animal being

AU - Ley, Jakob P.

AU - Widder, Sabine

AU - Somoza, Veronika

AU - Lieder, Barbara

AU - Zaunschirm, Mathias

AU - Krammer, Gerhard

N1 - Derwent Primary Accession Number: 2014-P72244 [59]

PY - 2014/8/21

Y1 - 2014/8/21

N2 - NOVELTY - A non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes, involves orally administering composition comprising at least one alkamide to a human or an animal being. USE - As non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes (claimed). ADVANTAGE - The composition reduces uptake of free fatty acids in the adipocytes and at the same time stimulates the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. The composition is thus perfectly suitable to counteract any undesired gain of weight. The alkamide compound counteracts overweight and its associated negative physical and mental factors. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) compositions for oral ingestion comprising at least one alkamide selected from 2E,4E-decadienic acid-N-isobutylamide (trans-pellitorine); 2E,4Z-decadienic acid-N-isobutylamide (cis-pellitorine); 2Z,4Z-decadienic acid-N-isobutylamide; 2Z,4E-decadienic acid-N-isobutylamide, 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2R)-2-methylbutylamide); 2E,4Z-decadienic acid-N-(2-methylbutyl)amide; 2E,4E-decadienic acid-N-piperidine (achilleamide); 2E-decenoic acid-N-isobutylamide; 2E,6Z,8E-decatrienoic acid N-isobutylamide (spilanthol); 2E,6Z,8E-decatrienoic acid N-((2S)-2-methylbutyl)amide (homospilanthol); 2E,6Z,8E-decatrienoic acid-N-((2R)-2-methylbutyl)amide; 2E-decen-4-inoic acid-N-isobutyl amide; 2Z-decen-4-inoic acid N-isobutyl amine; 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-methylpropyl)amide ( alpha -sanshool); 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( alpha -hydroxysanshool); 2E,6E,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( beta -hydroxysanshool; 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylpropyl)amide ( gamma -hydroxysanshool); 2E,4E,8E,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylprypyl)amide ( gamma -hydroxyisosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methyl-2-propenyl)amide ( gamma -dehydrosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methylpropyl)amide ( gamma -sanshool); 2E,4E,8Z,11Z-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (bungeanool), 2E,4E,8Z,11E-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (isobungeanool), 2E,4E,8Z-tetradecatrienoic acid N-(2-hydroxy-2-methylpropyl)amide (dihydrobungeanool) and 2E,4E-tetradecadienoic acid N-(2-hydroxy-2-methylpropyl)amide (tetrahydrobungeanool); and (2) use of alkamides as system to be orally ingested to reduce appetite and/or create a feeling of satiety and/or reduce the resorption of calories and/or for mood-enhancing purposes.

AB - NOVELTY - A non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes, involves orally administering composition comprising at least one alkamide to a human or an animal being. USE - As non-therapeutic process for the reduction of appetite and/or to create a feeling of satiety and/or to reduce caloric resorption and/or for mood-enhancing purposes (claimed). ADVANTAGE - The composition reduces uptake of free fatty acids in the adipocytes and at the same time stimulates the release of serotonin and dopamine, which leads to a reduction of appetite, a feeling of satiety and a positive mood. The composition is thus perfectly suitable to counteract any undesired gain of weight. The alkamide compound counteracts overweight and its associated negative physical and mental factors. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) compositions for oral ingestion comprising at least one alkamide selected from 2E,4E-decadienic acid-N-isobutylamide (trans-pellitorine); 2E,4Z-decadienic acid-N-isobutylamide (cis-pellitorine); 2Z,4Z-decadienic acid-N-isobutylamide; 2Z,4E-decadienic acid-N-isobutylamide, 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2S)-2-methylbutyl)amide; 2E,4E-decadienic acid-N-((2R)-2-methylbutylamide); 2E,4Z-decadienic acid-N-(2-methylbutyl)amide; 2E,4E-decadienic acid-N-piperidine (achilleamide); 2E-decenoic acid-N-isobutylamide; 2E,6Z,8E-decatrienoic acid N-isobutylamide (spilanthol); 2E,6Z,8E-decatrienoic acid N-((2S)-2-methylbutyl)amide (homospilanthol); 2E,6Z,8E-decatrienoic acid-N-((2R)-2-methylbutyl)amide; 2E-decen-4-inoic acid-N-isobutyl amide; 2Z-decen-4-inoic acid N-isobutyl amine; 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-methylpropyl)amide ( alpha -sanshool); 2E,6Z,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( alpha -hydroxysanshool); 2E,6E,8E,10E-dodecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide ( beta -hydroxysanshool; 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylpropyl)amide ( gamma -hydroxysanshool); 2E,4E,8E,10E,12E-tetradecapentaenoic acid N-(2-hydroxy-2-methylprypyl)amide ( gamma -hydroxyisosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methyl-2-propenyl)amide ( gamma -dehydrosanshool); 2E,4E,8Z,10E,12E-tetradecapentaenoic acid N-(2-methylpropyl)amide ( gamma -sanshool); 2E,4E,8Z,11Z-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (bungeanool), 2E,4E,8Z,11E-tetradecatetraenoic acid N-(2-hydroxy-2-methylpropyl)amide (isobungeanool), 2E,4E,8Z-tetradecatrienoic acid N-(2-hydroxy-2-methylpropyl)amide (dihydrobungeanool) and 2E,4E-tetradecadienoic acid N-(2-hydroxy-2-methylpropyl)amide (tetrahydrobungeanool); and (2) use of alkamides as system to be orally ingested to reduce appetite and/or create a feeling of satiety and/or reduce the resorption of calories and/or for mood-enhancing purposes.

M3 - Patent

M1 - US2014234412-A1; EP2767174-A1

ER -